Logo

American Heart Association

  155
  0


Final ID: MDP110

Nighttime home blood pressure was a crucial indicator in predicting adverse outcomes for patients with stage B heart failure

Abstract Body (Do not enter title and authors here): Background: Stage B heart failure (HF) was associated with increased cardiovascular and HF events. Hypertension is a risk factor for these events in Stage B HF. Nighttime blood pressure (BP) is more strongly associated with cardiovascular events than daytime BP, but nighttime home BP measurement is not widely used.
Method: We analyzed 573 stage B HF patients with at least one cardiovascular risk factor who underwent home BP monitoring. Stage B HF was defined as BNP ≥35pg/ml, or NT-proBNP ≥125pg/ml, Troponin T >0.014ng/ml, LVEF <50%, enlarged left ventricular dimensions in diastole (≥60mm in men and ≥54mm in women), enlarged left atrium (>40mm), or increased left ventricular mass (>115g/m2 in men and >95g/m2 in women). Morning, evening, and nighttime home BP were measured by home BP devices, and cardiovascular events were followed up.
Results: During a mean follow-up of 7.6 ± 3.6 years, 65 cardiovascular events occurred. Morning, evening, and nighttime home SBP were higher in the event group than in the non-event group (146±19 vs 140±14 mmHg, p=0.01, 137±17 vs 131±14 mmHg, p<0.01, 129±16 vs 123±14 mmHg, p<0.01, respectively). Kaplan Meier analysis showed that the high BP cut-off group defined by HT guidelines had significantly higher incidents of events in office, morning, and nighttime home SBP (p=0.03, p=0.02, p<0.01, respectively)(Figure). In multivariate Cox regression analysis adjusting for significant variables, nighttime home SBP >120mmHg was a significant predictor of the outcome (Hazard Ratio 2.03, 95% Confidence Interval: 1.13-3.65, p=0.02).
Conclusions: Elevated nighttime home BP was a significant predictor for cardiovascular outcomes in stage B HF patients.
  • Komori, Takahiro  ( Jichi Medical University , Tochigi-ken , Japan )
  • Hoshide, Satoshi  ( JICHI MIDICAL UNIVERSITY , Shimotsuke , Japan )
  • Kario, Kazuomi  ( JICHI MEDICAL UNIVERSITY , Tochigi-ken , Japan )
  • Author Disclosures:
    Takahiro Komori: DO NOT have relevant financial relationships | Satoshi Hoshide: DO NOT have relevant financial relationships | Kazuomi Kario: DO have relevant financial relationships ; Research Funding (PI or named investigator):Omuron Healthcare Co. Ltd.:Active (exists now) ; Research Funding (PI or named investigator):A&D Co Ltd.:Active (exists now) ; Research Funding (PI or named investigator):Fukuda Denshi Co. Ltd.:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Hemodynamics of Heart Failure

Saturday, 11/16/2024 , 11:10AM - 12:35PM

Moderated Digital Poster Session

More abstracts on this topic:
Assessing the Role of Charlson Comorbidity Index in Predicting Mortality Among Patients Requiring Rapid Response Team within 24 Hours of Admission

Salamatbad Gidon, Palati Sai, Lin Kuan-yu, Leung Christian, Wang Cassie, Jassal Ajay, Li Shuojohn, Guntaka Saimanoj, Chang Joshua, Jnani Jack, Patel Pushpendra, Cyr Andrew, Weintraub Spencer, Griffin Matthew, Alvarez Villela Miguel, Pierce Matthew, Shknevskiy Shusterman Vlad, Bhatt Madhav, Suleman Saman, Nuvvula Sri, Lin Allan, Dahal Kripa, Elkhechen Nader

A First-In-Human Phase 1 Study of the Safety, Tolerability, and Pharmacodynamics of REGN7544, a Novel Natriuretic Peptide Receptor 1–Blocking Monoclonal Antibody

Ahmed Mohsin, Morton Lori, Olenchock Benjamin, Herman Gary, Wynne Chris, Marin Ethan, Tuckwell Katie, Xu Meng, Cheng Xiping, Redington Emily, Koyani Bharatkumar, Mateo Katrina, Thakur Mazhar, Devalaraja-narashimha Kishor

You have to be authorized to contact abstract author. Please, Login
Not Available